RHHBY
Roche Holding AG
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Neutral
-1/100
Last price
52.55
▲ 0.04 (0.08%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
52.51
Day high
53.07
Day low
52.06
Volume
205.15K
Market cap
$334.96B
P/E (TTM)
21.80
52W range
40.07 – 60.85
Trailing performance
Returnvs SPY
1W
+0.57%
-1.4%
1M
-4.40%
-5.6%
3M
+1.53%
-3.0%
6M
+6.48%
-11.7%
YTD
+1.90%
-12.3%
1Y
+16.00%
-0.4%
3Y
+54.88%
-27.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RHHBY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$334.96B
Enterprise value$362.56B
Revenue (TTM)$62.96B
Gross profit$46.69B
EBITDA$23.96B
Net income$12.34B
EPS (TTM)$2.41
Free cash flow$10.32B
Total cash$9.73B
Total debt$33.31B
Book value / share$6.33
Shares outstanding5.52B
Float5.79B
Short % of float—
Dividend yield2.95%
Beta (5Y)0.33
Valuation & profitability ratios
Trailing P/E21.80
Forward P/E15.58
PEG ratio1.60
Price / sales—
Price / book8.30
EV / revenue5.76
EV / EBITDA15.13
Gross margin74.17%
Operating margin36.20%
Profit margin19.60%
Return on equity38.11%
Return on assets13.51%
Debt / equity90.72
Current ratio1.23
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $63.36B | $62.40B | $60.44B | $65.81B | +1.5% |
| Operating revenue | $63.36B | $62.40B | $60.44B | $65.81B | +1.5% |
| Cost of revenue | $16.64B | $16.28B | $16.36B | $19.74B | +2.2% |
| Gross profit | $46.71B | $46.11B | $44.08B | $46.08B | +1.3% |
| Research & development | $13.35B | $15.30B | $14.20B | $15.22B | -12.8% |
| Selling, general & admin | $15.16B | $14.90B | $14.88B | $14.20B | +1.8% |
| Total operating expense | $28.23B | $32.70B | $28.69B | $28.60B | -13.6% |
| Operating income | $18.48B | $13.42B | $15.39B | $17.48B | +37.7% |
| Net interest income | -$1.14B | -$1.15B | -$814.00M | -$673.00M | +1.4% |
| Pre-tax income | $16.97B | $11.79B | $14.08B | $16.33B | +43.9% |
| Tax provision | $3.17B | $2.61B | $1.72B | $2.80B | +21.8% |
| Net income | $12.88B | $8.28B | $11.50B | $12.42B | +55.6% |
| Net income to common | $12.88B | $8.28B | $11.50B | $12.42B | +55.6% |
| Basic EPS | 2.02 | 1.30 | 1.80 | 1.94 | +55.7% |
| Diluted EPS | 2.01 | 1.29 | 1.79 | 1.92 | +55.6% |
| EBIT | $18.32B | $13.20B | $15.08B | $17.02B | +38.8% |
| EBITDA | $21.70B | $16.62B | $18.54B | $20.86B | +30.6% |
| Basic shares | 6.37B | 6.38B | 6.39B | 6.40B | -0.1% |
| Diluted shares | 6.42B | 6.42B | 6.43B | 6.46B | +0.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $5.58B | $6.97B | $5.38B | $4.99B | -20.0% |
| Cash & short-term investments | $15.48B | $17.32B | $10.51B | $9.77B | -10.6% |
| Accounts receivable | $12.39B | $12.01B | $11.64B | $12.12B | +3.2% |
| Inventory | $7.48B | $7.61B | $7.75B | $8.61B | -1.7% |
| Total current assets | $38.73B | $40.04B | $33.45B | $33.82B | -3.3% |
| Property, plant & equipment | $22.93B | $23.74B | $22.94B | $24.21B | -3.4% |
| Goodwill & intangibles | $26.81B | $25.18B | $24.22B | $20.50B | +6.5% |
| Total assets | $100.70B | $101.80B | $90.47B | $88.15B | -1.1% |
| Total current liabilities | $28.00B | $27.02B | $24.82B | $27.24B | +3.6% |
| Current debt | $4.21B | $3.93B | $4.40B | $3.96B | +7.0% |
| Long-term debt | $27.43B | $30.72B | $24.81B | $21.39B | -10.7% |
| Total debt | $33.19B | $36.35B | $30.78B | $26.54B | -8.7% |
| Total liabilities | $62.82B | $65.64B | $57.20B | $56.14B | -4.3% |
| Retained earnings | $48.84B | $43.84B | $42.35B | $38.94B | +11.4% |
| Shareholder equity | $33.80B | $31.77B | $29.32B | $27.99B | +6.4% |
| Working capital | $10.73B | $13.01B | $8.62B | $6.58B | -17.6% |
| Net tangible assets | $6.99B | $6.59B | $5.10B | $7.49B | +6.1% |
| Shares issued | 809.25M | 809.25M | 809.25M | 809.25M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $13.80B | $9.19B | $12.36B | $13.53B | — | +50.2% |
| Depreciation & amortisation | $3.39B | $3.42B | $3.46B | $3.84B | — | -1.1% |
| Stock-based compensation | $857.00M | $855.00M | $830.00M | $738.00M | — | +0.2% |
| Change in working capital | -$1.66B | $1.16B | -$1.11B | -$2.42B | — | -242.7% |
| Operating cash flow | $18.85B | $20.09B | $16.09B | $17.80B | — | -6.2% |
| Capital expenditure | -$5.78B | -$5.01B | -$4.65B | -$4.55B | — | -15.4% |
| Investing cash flow | -$8.54B | -$11.39B | -$10.64B | -$2.92B | — | +25.0% |
| Share buybacks | — | — | — | $0 | -$18.99B | — |
| Dividends paid | -$7.73B | -$7.65B | -$7.59B | -$7.45B | — | -1.1% |
| Financing cash flow | -$11.37B | -$6.82B | -$4.24B | -$16.27B | — | -66.7% |
| Free cash flow | $13.07B | $15.09B | $11.45B | $13.25B | — | -13.3% |
| End cash position | $5.58B | $6.97B | $5.38B | $4.99B | — | -20.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $5.45B | $5.58B | — | -2.4% |
| Cash & short-term investments | $9.73B | $15.48B | $12.03B | -37.1% |
| Accounts receivable | $12.91B | $12.39B | $11.92B | +4.2% |
| Inventory | $8.09B | $7.48B | $7.60B | +8.2% |
| Total current assets | $35.44B | $38.73B | $35.70B | -8.5% |
| Property, plant & equipment | $23.41B | $22.93B | $22.87B | +2.1% |
| Goodwill & intangibles | $27.09B | $26.81B | $24.33B | +1.0% |
| Total assets | $98.20B | $100.70B | $94.77B | -2.5% |
| Total current liabilities | $28.85B | — | $27.58B | — |
| Current debt | $6.58B | $4.21B | — | +56.5% |
| Long-term debt | $25.22B | $27.43B | $26.46B | -8.0% |
| Total debt | $31.80B | $33.19B | — | -4.2% |
| Total liabilities | $61.48B | $62.82B | $61.72B | -2.1% |
| Retained earnings | $47.55B | $48.84B | — | -2.6% |
| Shareholder equity | $32.69B | $33.80B | $28.68B | -3.3% |
| Working capital | $6.59B | $10.73B | — | -38.6% |
| Net tangible assets | $5.60B | $6.99B | $4.35B | -19.8% |
| Shares issued | 809.25M | 809.25M | 809.25M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $15.73B | +5.5% |
| Next quarter | — | — | $16.43B | +5.0% |
| Current year | 3.13 | 5 | $62.80B | +2.1% |
| Next year | 3.37 | 5 | $65.64B | +4.5% |
Analyst targets & ownership
Mean target$60.44
High target$67.10
Low target$52.00
Implied upside15.02%
Analyst count7
ConsensusBUY
Strong buy / Buy2 / 2
Hold4
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions0.52%
Institutions holding129
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
53.15
-1.12% from price
SMA 20
53.77
-2.27% from price
SMA 50
55.02
-4.48% from price
SMA 100
53.26
-1.32% from price
SMA 200
53.21
-1.24% from price
EMA 12
53.16
-1.14% from price
EMA 26
53.83
-2.38% from price
EMA 50
54.02
-2.71% from price
RSI (14)
41.3
Neutral
MACD (12,26,9)
-0.68
Hist -0.20
ATR (14)
0.94
1.78% of price
Realised vol 30D
24.1%
Annualised
Bollinger upper
56.19
20, 2σ
Bollinger lower
51.35
20, 2σ
50 / 200 cross
Golden
55.02 vs 53.21
Trend bias
Below 200
-1.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.32
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
24.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-21.8%
Peak to trough
Max drawdown 5Y
-45.2%
Peak to trough
ATR 14
0.94
1.78% of price
Beta (reported)
0.33
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 12, 23 | TD Cowen | MAINTAINED | Market Perform | Market Perform |
| Nov 15, 22 | Cowen & Co. | DOWNGRADE | Outperform | Market Perform |
| Jun 27, 22 | Cowen & Co. | MAINTAINED | — | Outperform |
| Jul 8, 21 | Deutsche Bank | UPGRADE | Hold | Buy |
| Jan 28, 19 | Argus Research | INITIATED | — | Buy |
| Jan 28, 19 | Credit Suisse | UPGRADE | Underperform | Neutral |
| Nov 19, 18 | Goldman Sachs | DOWNGRADE | Conviction Buy | Buy |
| May 25, 18 | Credit Suisse | DOWNGRADE | Neutral | Underperform |
| May 10, 18 | Bernstein | DOWNGRADE | Outperform | Market Perform |
| Jan 8, 15 | UBS | DOWNGRADE | Buy | Neutral |
| Mar 13, 14 | Morgan Stanley | INITIATED | — | Overweight |
| Aug 22, 12 | JP Morgan | UPGRADE | Neutral | Overweight |
Dividends & splits
Forward rate$1.55 / yr
Forward yield2.95%
5-year avg yield3.17%
Payout ratio64.59%
Ex-dividend dateMar 13, 2026
Next pay dateApr 22, 2026
Last split2:1
Split dateFeb 27, 2014
Headlines
Nurix Says First Patient Enrolled in Phase 1b/2 Lymphocytic Leukemia Combination Study
MT Newswires · 13m ago
Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC
PR Newswire · 4h ago
Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal
GuruFocus.com · 13h ago
AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says
MT Newswires · 16h ago
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
BioPharma Dive · 17h ago
Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
Pharmaceutical Technology · 22h ago
Analog Devices Insider Sold Shares Worth $3,969,400, According to a Recent SEC Filing
MT Newswires · 1d ago
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.